Newsfox

SENDER

AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44 24
E-Mail: nina.roth@aoporphan.com

KEYWORDS:

Polycythaemia Vera

BESREMi

Ropeginterferon

AOP Orphan

PharmaEssentia

Download Photos

AOP Orphan Pharmaceuticals Aktiengesellschaft (21 releases)

AOP Orphan reports full validity of arbitral award against PharmaEssentia

Today the Higher Regional Court of Frankfurt declared enforceable the October 2020 award pertaining to the arbitration between AOP Orphan and PharmaEssentia Corp. The agreement between AOP Orphan and PharmaEssentia Corp.remains in full force and effect, and AOP Orphan is entitled to damages from PharmaEssentia of approx. EUR 142 million. [more]

AOP Orphan reports full validity of arbitral award against PharmaEssentia
2021-03-25, pts20210325027 Science/Technology, Health/Medicine

BESREMi® (Ropeginterferon?alfa-2b) deemed safe and efficacious by the US FDA
2021-03-15, pts20210315022 Science/Technology, Health/Medicine

European ICU Drug Supports Patients in Canada
2021-02-01, pts20210201018 Health/Medicine, Companies/Finance

AOP Orphan: PAH Treatment for Patients in Argentina
2021-01-26, pts20210126026 Health/Medicine, Companies/Finance

AOP Orphan announces 5-year results on BESREMi® (Ropeginterferon alfa-2b) in PV at the ASH Annual Meeting 2020
2020-12-08, pts20201208021 Health/Medicine, Science/Technology

AOP Orphan announces 5-year results on BESREMi® (Ropeginterferon alfa-2b) in PV at the ASH Annual Meeting 2020
2020-12-07, pts20201207001 Science/Technology, Health/Medicine

ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®
2020-10-28, pts20201028019 Companies/Finance, Science/Technology

AOP Orphan, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia
2019-05-13, pts20190513036 Science/Technology, Health/Medicine

AOP Orphan announces EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV)
2019-02-20, pts20190220022 Health/Medicine, Science/Technology

AOP ORPHAN AND CHORD ANNOUNCE A PARTNERSHIP TO DEVELOP CRD1 (CLADRIBINE) FOR TREATMENT OF ORPHAN AUTOIMMUNE DISEASES
2019-01-03, pts20190103017 Science/Technology, Health/Medicine

1 2 3 Next »

PRESS BOX Interactive

News Releases via
RSS-Feed

Subscribe
News Releases

Create digital
Press Folder (pdf)

Embedd News Releases
in your Webseite

Social Media